Citius Pharmaceuticals (CTXR) Share-based Compensation (2013 - 2026)

Citius Pharmaceuticals (CTXR) has reported Share-based Compensation for 14 consecutive years, with $11.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 103.75% year-over-year to $11.3 million; the trailing twelve-month figure through Jun 2026 stood at $11.3 million (up 103.75% YoY), and the FY2025 full-year result was $11.5 million, down 2.85% from the prior year.
• Share-based Compensation advanced to $11.3 million in Q2 2026 per CTXR's latest filing, from $3.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $17.4 million in Q4 2023 and bottomed at $976675.0 in Q3 2022.
• Historically, Share-based Compensation has averaged $8.4 million across 5 years, with a median of $9.3 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation surged 1364.75% in 2022, then sank 85.48% in 2024.
• Over 5 years, Share-based Compensation stood at $13.3 million in 2022, then jumped by 31.24% to $17.4 million in 2023, then tumbled by 85.48% to $2.5 million in 2024, then surged by 348.22% to $11.3 million in 2025, then changed by 0.0% to $11.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $11.3 million, $3.8 million, and $11.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.